Home > Neurology > EAN 2020 > Multiple Sclerosis > Eculizumab in NMOSD: the PREVENT study

Eculizumab in NMOSD: the PREVENT study

In the phase 3, randomised, double-blind PREVENT study, eculizumab was effective in aquaporin-4 immunoglobulin G-positive neuromyelitis optica spectrum disorder (NMOSD) in different regions of the world, despite significant differences in standard of care [1]. Long-term results from the PREVENT study’s open-label extension (OLE) supported the efficacy of eculizumab monotherapy in reducing relapse risk [2].

The PREVENT study assessed the efficacy and safety of eculizumab in adult patient populations in Europe, the Americas, and Asia-Pacific. Patients were randomised to eculizumab or placebo. Stable doses of concomitant immunosuppressive therapy (IST) were allowed. IST use at baseline was much lower in Europe than in the other 2 regions, so that a large proportion of European participants in the placebo group had no medication at all. Compared with placebo, eculizumab significantly reduced relapse...



please login to read the entire article:


You need to register to read the entire article, please do so now.





Posted on